G. Steger

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Michael Gnant, Martin Filipits, Richard Greil et al. · Annals of Oncology · 2013 · 392 citations · Full text

Surgical Oncology, Breast Oncology, Recurrence Score +10

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial

Meinolf Karthaus, Albrecht Kretzschmar, H. Kröning et al. · Annals of Oncology · 2005 · 219 citations · Full text

Venous Disease, Oncology, Venous Thrombosis +10

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

David Miles, A. Chan, Gilles Romieu et al. · Journal of Clinical Oncology · 2008 · 213 citations

Metastatic Breast Cancer, Oncology, Lba1011 Background +15

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

Dusan Kotasek, G. Steger, Wylam Faught et al. · European Journal of Cancer · 2003 · 139 citations

Hematological Malignancy, Darbepoetin Alfa, Oncology +9

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

Ursula Wiedermann, C Wiltschke, Joanna Jasińska et al. · Breast Cancer Research and Treatment · 2009 · 120 citations

Metastatic Breast Cancer, Breast Oncology, Cancer Immunosurveillance +8